New to peptides? Start with the foundations ->
The dad-test answer
Glucosamine is an oral supplement with mixed but real evidence for osteoarthritis pain - cheap, accessible, and worth a trial. BPC-157 is a research peptide with strong animal-study evidence for tendon and connective tissue healing but no human RCTs. Glucosamine is the safe first move for joint pain; BPC-157 is the bigger-upside option for tendon and acute soft-tissue injury when glucosamine isn't enough.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| knee osteoarthritis, daily joint pain |
glucosamine GAIT trial (Clegg et al., NEJM 2006) and follow-up data show modest pain relief in moderate-to-severe knee osteoarthritis; oral, cheap, and safe. |
| acute tendon injury, partial tear, post-surgery |
bpc-157 Gwyer et al. 2010 Achilles tendon model and broader animal data show accelerated tendon healing - this is BPC-157's strongest evidence axis. |
| regulatory and safety record |
glucosamine Decades of supplement safety data; BPC-157 is research-use-only without FDA approval or human RCT data. |
| speed of effect for acute injury |
bpc-157 Operator track record reports tendon and ligament response in 3-4 weeks; glucosamine typically requires 8-12 weeks of daily use for any pain signal. |
What the head-to-head data shows
Glucosamine is not a peptide - it's an amino sugar sold as a supplement (sulfate or hydrochloride form) for osteoarthritis. We're including it because anyone with joint or tendon pain reasonably compares them. The strongest glucosamine signal is in moderate-to-severe knee osteoarthritis; Clegg et al., NEJM 2006 (GAIT trial) randomized 1,583 patients to glucosamine, chondroitin, the combination, celecoxib, or placebo - the combination showed modest benefit in the moderate-to-severe pain subgroup. European trials have been more positive; AHRQ and OARSI guidelines remain mixed. BPC-157's evidence sits on animal studies; the foundational Achilles tendon paper is Gwyer et al. 2010. Soriano et al. 2025 systematic review surveyed BPC-157's emerging use in orthopedic sports medicine - finding consistent animal-study signal, sparse but growing case-report data, and zero randomized human trials. Lee 2021 reported intra-articular BPC-157 for knee pain in 11 of 12 patients - small case series, not a controlled trial.
Our honest call
For someone with chronic knee or hip osteoarthritis, glucosamine is the right first move - cheap, accessible at any pharmacy, generally well tolerated, and an 8-12 week trial is easy to evaluate. If glucosamine doesn't help and the issue is daily wear-and-tear arthritis, weight loss and proper PT remain the higher-leverage moves. For an acute tendon injury, partial tear, or post-surgical recovery where the goal is speeding tissue repair (not just managing chronic joint pain), BPC-157 is the protocol with the actual mechanism evidence behind it - even though it's animal-grade. We have used BPC-157 personally for rotator-cuff recovery; we have not personally tracked glucosamine response in detail. The honest framing: glucosamine for chronic OA, BPC-157 for acute tendon. Don't use either as a substitute for proper PT and load management.
Sources and citations
- Clegg et al., GAIT trial glucosamine in knee OA, NEJM 2006 (PMID 16495392)
- Gwyer et al., BPC-157 in Achilles tendon healing, J Orthop Res 2010 (PMID 19514371)
- Soriano et al., BPC-157 in orthopedic sports medicine systematic review, 2025 (PMID 40756949)
- Lee et al., Intra-articular BPC-157 for knee pain, Altern Ther Health Med 2021 (PMID 34324435)
- OARSI Guidelines for the non-surgical management of knee osteoarthritis
Where to go next
- Full BPC-157 directory entry
- BPC-157 dosing breakdown
- What are peptides - if you skipped the foundation
- All Protocol One comparisons
- How peptides actually work
- Subscribe to the dispatch
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.